Research Radar

What it is

Not a summary of the news. Three computed signals, run monthly against the full Agewell Brief archive:

• Confidence shifts within a topic — pairs of briefs under the same topic where the later one sits higher on the evidence ladder (speculative → contested → emerging → established) than the earlier one, with a real gap in time. Same-day variance across two takes on one topic doesn't count. This tracks a topic's confidence, not one mechanism proven out — the two briefs in a pair are often different findings that happen to share a topic tag.
• Cross-framework convergence — historical antecedents independently cited by briefs in unrelated categories, surfacing which underlying mechanisms disparate current research is converging on without being told to look for it.
• Trial registry activity (prototype) — which named compounds or interventions mentioned in the archive already have real trials on ClinicalTrials.gov, and at what phase, sponsored by whom. Coverage is partial today (most briefs describe a bench-level mechanism with no named intervention yet); reported honestly rather than padded.

Every entry links to the specific, dated brief — or trial ID — that produced it. Nothing is inferred without a citation you can open and check yourself. Full methodology: agewellbrief.com/research-radar-methodology. See a real sample issue, computed live from the current archive.

Who this is for

• Longevity biotech investors who want an early, falsifiable signal on which mechanisms are gaining real support, not just press coverage.
• R&D teams at supplement and longevity brands scanning for where the science is actually moving before committing formulation budget.
• Analysts who want a sourced starting point for diligence, not a black-box AI summary.

Said plainly: the archive is still young and trial-registry coverage is partial today (see the methodology page). This is an early, falsifiable signal to track alongside your own diligence — not a substitute for it.

How it works

One issue a month, delivered by email. Each issue covers what moved since the last one — new confidence shifts, new convergence hits, new trial-registry activity — plus a running methodology note so you always know exactly what's being measured and why. Monthly rather than weekly on purpose: a thin week padded to hit a schedule is worse than no issue at all, and every finding here has to be real, computed from the archive — never a summary written to fill space.

Price

$399/month, or $3,990/year. No trial, no self-serve checkout yet — every subscription starts as a conversation so the first issue actually reflects what you're trying to track.